Complement system biomarkers in epilepsy by Kopczynska, Maja et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/112949/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Kopczynska, Maja, Zelek, Wioleta, Vespa, Simone, Touchard, Samuel, Wardle, Mark, Loveless,
Samantha, Thomas, Rhys H., Hamandi, Khalid and Morgan, B. Paul 2018. Complement system
biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60 , pp. 1-7.
10.1016/j.seizure.2018.05.016 file 
Publishers page: http://dx.doi.org/10.1016/j.seizure.2018.05.016
<http://dx.doi.org/10.1016/j.seizure.2018.05.016>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
 Complement	biomarkers	in	Epilepsy	
Page	1	
 
Complement	System	Biomarkers	in	Epilepsy	
	
	
Maja	 Kopczynska
1
,	 Wioleta	 M.	 Zelek
1
,	 Simone	 Vespa
1
,	 Samuel	 Touchard
1
,	 Mark	 Wardle
2
,	
Samantha	Loveless
2
,	Rhys	H.	Thomas
2,3
,	Khalid	Hamandi
2
,	B.	Paul	Morgan
1
	
	
1. Systems	 Immunity	 Research	 Institute	 and	 Division	 of	 Psychological	 Medicine	 and	
Clinical	Neurology,	School	of	Medicine,	Cardiff	University,	Cardiff,	CF14	4XN,	UK.	
2. Department	of	Neurology,	University	Hospital	of	Wales,	Cardiff,	CF14	4XW,	UK.	
3. Institute	 of	Neuroscience,	Henry	Wellcome	Building,	Newcastle	University,	Newcastle	
upon	Tyne,	NE2	4HH,	UK.	
	
Corresponding	author	
Prof	B.	Paul	Morgan;	Henry	Wellcome	Building,	School	of	Medicine,	Cardiff	University,	Cardiff	
CF144XN.	Email:	Morganbp@cardiff.ac.uk	
	
	
	
	 	
 Complement	biomarkers	in	Epilepsy	
Page	2	
 
	
Abstract	
	
Purpose:	To	explore	whether	complement	dysregulation	occurs	in	a	routinely	recruited	clinical	
cohort	of	epilepsy	patients,	and	whether	complement	biomarkers	have	potential	to	be	used	as	
markers	of	disease	severity	and	seizure	control.	
Methods:	 Plasma	 samples	 from	 157	 epilepsy	 cases	 (106	 with	 focal	 seizures,	 46	 generalised	
seizures,	 5	 unclassified)	 and	 54	 controls	 were	 analysed.	 Concentrations	 of	 10	 complement	
analytes	(C1q,	C3,	C4,	factor	B	[FB],	terminal	complement	complex	[TCC],	 iC3b,	factor	H	[FH],	
Clusterin	 [Clu],	 Properdin,	 C1	 Inhibitor	 [C1Inh]	 plus	 C-reactive	 protein	 [CRP]	were	measured	
using	 enzyme	 linked	 immunosorbent	 assay	 (ELISA).	 Univariate	 and	 multivariate	 statistical	
analysis	were	used	to	test	whether	combinations	of	complement	analytes	were	predictive	of	
epilepsy	 diagnoses	 and	 seizure	 occurrence.	 Correlation	 between	 number	 and	 type	 of	 anti-
epileptic	drugs	(AED)	and	complement	analytes	was	also	performed.	
Results:	We	found:	
1)	significant	differences	between	all	epilepsy	patients	and	controls	 for	TCC	(p˂	0.01)	and	FH	
(p˂	0.01)	after	performing	univariate	analysis.	
2)	 multivariate	 analysis	 combining	 six	 analytes	 (C3,	 C4,	 Properdin,	 FH,	 C1Inh,	 Clu)	 to	 give	 a	
predictive	value	(area	under	the	curve)	of	0.80	for	differentiating	epilepsy	from	controls.	
3)	significant	differences	in	complement	levels	between	patients	with	controlled	seizures	(n=65)	
in	 comparison	 with	 uncontrolled	 seizures	 (n=87).	 Levels	 of	 iC3b,	 Properdin	 and	 Clu	 were	
decreased	and	levels	of	C4	were	increased	in	patients	with	uncontrolled	seizures.		
4)	no	correlation	was	found	between	the	level	of	complement	biomarkers	and	the	number	of	
AEDs	 taken,	 but	 an	 association	 between	 some	 analyte	 levels	 and	 drug	 therapy	was	 seen	 in	
patients	taking	sodium	valproate,	clobazam,	and	perampanel.	
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Conclusion:	 This	 study	adds	 to	evidence	 implicating	complement	 in	pathogenesis	of	epilepsy	
and	may	allow	the	development	of	better	therapeutics	and	prognostic	markers	 in	the	future.	
Replication	in	a	larger	sample	set	is	needed	to	validate	the	findings	of	the	study.	
	
Highlights:	
• Plasma	complement	biomarkers	distinguish	epilepsy	patients	from	controls	(area	under	
the	curve:	0.8).	
• Plasma	 complement	 biomarkers	 differ	 between	 controlled	 and	 uncontrolled	 epilepsy	
patients.	
• The	data	implicate	complement	dysregulation	and	inflammation	in	the	pathogenesis	of	
epilepsy.	
	
Keywords:	inflammation;	predictors;	plasma;	seizures,	epilepsy,	biomarkers	
	
Abbreviations:	
FB	–	factor	B	
TCC	–	terminal	complement	complex		
FH	–	factor	H	
Clu	–	Clusterin	
C1Inh	–	C1	Inhibitor	
CRP	–	C-reactive	protein	
ELISA	–	enzyme	linked	immunosorbent	assay	
AED	–	anti-epileptic	drugs	
CNS	–	central	nervous	system	
WNRTB	–	Wales	Neuroscience	Research	Tissue	Bank	
BSA	–	bovine	serum	albumin	
PBS-T	–	phosphate-buffered	saline	containing	0.1%	Tween	
HRP	–	horseradish	peroxidase	
ROC	–	Receiver	Operating	Curve	
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AUC	–	area	under	the	curve	
MAC	–	membrane	attack	complex	
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Introduction	
Epilepsy	is	a	common	disease;	in	England	the	prevalence	of	people	with	epilepsy	who	take	anti-
epileptic	 medication	 is	 0.43-1.16%	 [1].	 The	 2017	 International	 League	 Against	 Epilepsy	
consensus	on	epilepsy	classification	highlights	the	 importance	of	defining	aetiology,	 including	
immune	causes
	
[2].	Despite	contemporary	advances	in	neuroimaging	and	clinical	genetics,	the	
aetiology	 of	 epilepsy	 is	 still	 unknown	 in	 over	 a	 third	 of	 cases	 and	 a	 third	 of	 patients	 have	
seizures	resistant	to	current	antiepileptic	drugs	(AEDs)
	
[3,4].	In	these	cases	resective	surgery	is	
the	best	current	option	and	can	be	curative,	particularly	 in	temporal	 lobe	epilepsy;	however;	
seizure	 recurrence	 occurs	 in	 up	 to	 half	 of	 patients	 within	 5	 years	 of	 operation
	
[5].	 Thus	 far	
precision	medicine	in	epilepsy	has	been	limited	to	the	realm	of	the	genetic	encephalopathies
	
[6].	 A	 better	 understanding	 of	 aetiology	 would	 enable	 more	 effective	 treatment,	 targeted	
towards	underlying	pathogenic	mechanisms	[7].		
	
Increasing	 evidence	 from	 experimental	 animal	 models	 and	 resected	 human	 brain	 tissue	
supports	 a	 role	 of	 the	 immune	 system	 in	 epilepsy	 [8].	 At	 the	 population	 level	 there	 are	
prevalence	correlations	between	auto-immune	disorders	and	epilepsy;	 the	 risk	of	epilepsy	 is	
3.8	 times	 greater	 in	 people	 with	 any	 one	 of	 12	 autoimmune	 disorders	 and	 even	 higher	 in	
children	 with	 autoimmunity	 [9].	 Systemic	 autoimmune	 disorders,	 such	 as	 systemic	 lupus	
erythematosus,	have	a	neurological	phenotype	that	includes	a	predeliction	for	seizures	[2].	The	
most	 studied	 forms	 of	 immune	 epilepsy	 are	 Rasmussen’s	 encephalitis,	 and	 the	 autoimmune	
encephalitidies	 associated	 with	 circulating	 antibodies	 [10].	 Currently,	 primary	 immune-
mediated	 epilepsies	 are	 recognised	 as	 neural	 autoantibody	 disorders	 affecting	 both	 cell-
surface	 expressed	 proteins	 such	 as	 LGI1	 and	 N-methyl-D-aspartate	 (NMDA)	 receptor,	 and	
intacellular	 proteins	 such	 as	 GAD	 [11].	 A	 study	 of	 neural	 auto-antibodies	 in	 epilepsies	 of	
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apparent	unknown	aetiology	suggested	that	immune	activation	may	explain	up	to	20%	of	non-
paraneoplastic	cases	[12].	
	
While	the	usefulness	of	autoantibody	measurements,	where	present,	as	diagnostic	biomarkers	
and	treatment	outcome	predictors	 is	 robust,	 the	mechanistic	nature	of	 the	relation	between	
autoantibodies	 and	 disease	 has	 yet	 to	 be	 elucidated	 in	most	 cases.	 Positive	 responses	 have	
been	 reported	 for	B	 cell	 ablation	 therapy	using	 rituximab	 in	 some	 cases,	 suggesting	 a	direct	
role	 of	 the	 autoantibodies	 in	 pathogenicity	 [13,14].	 Furthermore,	 an	 absence	 of	 neural	
autoantibodies	does	not	 rule	out	 the	 success	of	 immunotherapies,	or	 exclude	a	diagnosis	of	
limbic	 encephalitis	 [13,15].	 This	 lack	 of	 consensus	 and	 growing	 evidence	 of	 an	
immune/inflammatory	 component	 in	 epilepsy	 development	 makes	 it	 necessary	 to	 enlarge	
diagnostic	 and	 prognostic	 assessment	 to	 include	 other	 immunological	 biomarkers	 [16].	 In	
response	to	this	need,	the	involvement	of	different	immune	pathways	in	epilepsy	pathogenesis	
is	increasingly	investigated	in	animal	models	and	in	humans	[17-19].	
	
One	 such	 pathway	 is	 the	 complement	 system,	 a	major	 effector	 of	 innate	 immunity	 and	 an	
adjuvant	 of	 adaptive	 immunity.	 Complement	 comprises	 around	 30	 plasma	 and	 cell-surface	
proteins	that	interact	with	one	another	to	induce	a	series	of	inflammatory	responses	involved	
in	defence	against	infection	[20].	Complement	activation	in	the	CNS	is	increasingly	recognised	
to	 be	 associated	 with	 exacerbation	 and	 progression	 of	 tissue	 injury	 in	 degenerative	 and	
inflammatory	diseases	[21,22].	Dysregulation	of	the	complement	system	in	epilepsy	has	been	
observed	 both	 in	 human	 and	 animal	 studies	 [23-27].	 For	 example,	 sequential	 infusion	 of	
individual	 proteins	 of	 the	 membrane	 attack	 pathway	 (C5b6,	 C7,	 C8,	 and	 C9)	 into	 the	
hippocampus	 of	 awake,	 freely	 moving	 rats	 induced	 both	 behavioural	 and	 electrographic	
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seizures	 as	 well	 as	 neurotoxicity,	 suggesting	 a	 direct	 role	 for	 the	 complement	 system	 in	
epileptogenesis	[28].	
	
The	aim	of	this	study	was	to	identify	whether	changes	in	the	complement	system	occurred	in	
the	plasma	of	patients	with	epilepsy,	and	investigate	whether	plasma	complement	biomarkers	
could	be	used	in	diagnosis	or	stratification	related	to	epilepsy	syndrome	and	seizure	control.	
	
Materials	and	methods	
Hospital	Records	and	Samples	
Patients	were	 prospectively	 recruited	 through	 i)	 a	 secondary	 care	 adult	 epilepsy	 clinic,	 or	 ii)	
attendance	for	video	telemetry	as	part	of	pre-surgical	evaluation.	The	diagnosis	of	epilepsy	was	
confirmed	 and	 classified	 according	 to	 current	 criteria	 [5],	 and	 presented	 in	 Table	 1.	 No	
restriction	in	terms	of	epilepsy	syndrome	was	made	as	part	of	inclusion	criteria.	All	cases	and	
controls	 included	 in	 the	 study	 gave	 informed	 consent.	 Ethical	 approval	was	 granted	 through	
the	Wales	Neuroscience	Research	Tissue	Bank	(WNRTB).	Detailed	electroclinical	phenotyping,	
brain	imaging,	medication	and	seizure	type	and	frequency	at	the	time	of	sample	collection,	and	
for	 one	 year	 prior,	were	 obtained	 from	hospital	 records	 for	 all	 patients.	 Controlled	 epilepsy	
was	 defined	 as	 no	 seizure	 of	 any	 type	 in	 the	 past	 year.	 Relevant	 clinical	 variables	 and	 the	
results	 of	 investigations	 were	 entered	 into,	 and	 then	 extracted	 from,	 a	 customised	 clinical	
database	(PatientCare)	[29].	Plasma	samples	(157)	were	acquired	from	patients	with	epilepsy	
(106	 focal	 epilepsy,	 46	 generalised	 epilepsy,	 5	 unclassified	 or	 single	 seizure)	 and	 tested	
alongside	those	from	54	healthy	non-neurological	disease	controls	sourced	via	the	WNRTB.	The	
controls	 included	mostly	 staff	 or	 students	 consented	 for	 research	 and	 stored	 in	 the	 facility	
(WNRTB	 ethics	 REC#	 14/WA/0073).	 The	 presence	 of	 autoantibodies	 was	 tested	 as	 part	 of	
routine	clinical	practice	in	cases	where	there	was	clinically	assessed	suspicion	of	autoimmunity;	
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19	were	tested	for	anti-NMDA	(one	positive,	uncertain	significance),	21	were	tested	for	anti-
VGKC	(none	positive)	and	4	were	tested	for	anti-GAD	(none	positive).	Five	cases	had	co-existing	
thyroid	disease;	there	were	no	other	autoimmune	conditions	in	the	cohort.	
	
Immunoassays	
Eleven	 complement	 analytes	 were	 selected	 for	 this	 study,	 guided	 by	 reference	 to	 previous	
studies	of	complement	biomarkers	in	epilepsy	which	have	described	increased	serum	levels	or	
gene	expression	of	C3,	C4,	C1q,	iC3b	and	terminal	complement	complex	(TCC),	and	availability	
of	 reagents	 and	 in-house	 assays	 [23,24,26,28,30].	 The	 concentrations	of	 nine	 analytes:	 iC3b,	
C1q,	 C3,	 C4,	 Properdin,	 Factor	 B	 (FB),	 Factor	 H	 (FH),	 C1	 inhibitor	 (C1inh),	 and	 TCC	 were	
measured	using	established	 in-house	enzyme-linked	 immunosorbent	assays	 (ELISA)	 (Table	2).	
The	marker	set	was	chosen	to	interrogate	classical	(C1q,	iC3b,	C3,	C4),	alternative	(Properdin,	
FB,	 FH,	 iC3b)	 and	 terminal	 (TCC)	 activation	 pathways.	 The	 remaining	 two	 analytes	 Clusterin	
(Clu),	 a	 complement	 cascade	 regulator	 and	 C-reactive	 protein	 (CRP),	 a	 benchmark	 of	
inflammatory	 state,	were	measured	using	commercial	kits	 (CRP	and	Clusterin	DuoSet	ELISAs,	
R&D	 Systems,	 Abingdon,	 UK).	 The	 samples	 available	 for	 analysis	 comprised	 plasma	 aliquots	
that	 had	 been	 sepaerated	 promptly,	 stored	 at	 -80°C	 and	 not	 subjected	 to	 freeze-thaw.	 For	
ELISA,	Maxisorp	 (Nunc,	 Loughborough,	UK)	 plates	were	 coated	with	 afﬁnity-purified	 capture	
antibody	for	1	hour	at	room	temperature,	and	blocked	(1	hour	at	RT)	with	1%	bovine	serum	
albumin	(BSA)	in	phosphate-buffered	saline	containing	0.1%	Tween	20	(Sigma	Aldrich)	(PBS-T).	
After	washing	wells	in	PBS-T,	puriﬁed	protein	standards	or	serum	samples	optimally	diluted	in	
0.1%	 BSA	 in	 PBS-T,	 were	 added	 in	 duplicate	 and	 incubated	 for	 1.5	 hour	 at	 37°C.	 Different	
sample	dilutions	were	used	 for	different	assays	 (Table	2).	Wells	were	washed	3	x	with	PBS-T	
then	incubated	(1	hour)	at	RT	with	detection	antibody	(unlabelled	or	labelled	with	horseradish	
peroxidase	(HRP))	and	washed	3	x	with	PBS-T.	For	assays	using	unlabelled	detection	antibodies,	
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HRP	labelled	secondary	antibody	(anti-mouse	or	anti-rabbit	IgG	as	appropriate)	was	added	to	
wells,	 incubated	 and	 washed	 as	 above.	 Signals	 were	 detected	 using	 o-Phenylenediamine	
dihydrochloride	 (OPD,	 SIGMAFAST™,	Sigma-Aldrich)	and	absorbance	 (492nm)	was	measured.	
Standards	were	 included	on	each	plate	and	samples	 from	controls	and	cases	were	 randomly	
assigned	to	eliminate	assay	bias.	A	nonlinear	regression	model	was	used	to	ﬁt	standard	curves	
generated	 by	 ELISA.	 Total	 protein	 concentration	 (µg/ml)	 was	 automatically	 calculated	 by	
reference	to	the	standard	curve	using	GraphPad	Prism	version	5	(La	Jolla,	CA,	USA).	Detection	
limits,	working	ranges	and	assay	performance	were	determined	as	described	[31],	using	serum	
from	local	healthy	controls.	
	
Statistical	analysis	
Univariate	 statistical	 tests	 were	 performed	 using	 the	 Kruskal-Wallis	 test	 for	 comparison	
between	 healthy	 controls,	 focal	 epilepsy	 and	 generalised	 epilepsy,	 for	 each	 analyte.	 Mann-
Whitney	U-test	was	used	for	comparison	between	focal	epilepsy	and	generalised	epilepsy	for	
each	analyte.	Stepwise	logistic	regression	models	were	tested,	including	the	measured	analytes	
together	with	co-variates	sex	and	age	to	adjust	 for	their	 impact	on	measured	analytes	 in	the	
cohort.	The	selected	models	were	then	tested	using	Receiver	Operating	Curve	(ROC)	analyses,	
with	 leave-one-out	cross-validation.	Differences	 in	complement	 levels	between	patients	with	
controlled	 seizures	 in	 comparison	 with	 uncontrolled	 seizures	 were	 tested	 using	 the	 Mann-
Whitney	 U-test,	 while	 correlation	 between	 complement	 analytes	 and	 frequency	 of	 seizures,	
and	between	antiepileptic	drugs	and	concentrations	of	complement	analytes,	was	investigated	
using	 the	Spearman	test.	Differences	 in	complement	concentrations	between	patients	 taking	
or	not	taking	a	given	drug	were	tested	using	the	Mann-Whitney	U-test.	Due	to	the	conservative	
nature	 of	 multiple	 testing	 procedures	 and	 the	 interdependence	 of	 our	 assays,	 the	 p-values	
derived	 from	 the	 univariate	 analyses	 were	 not	 corrected	 for	 multiple	 comparisons.	 Power	
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calculations	 were	 performed,	 to	 evaluate	 how	many	 samples	 would	 be	 needed	 to	 observe	
significant	differences	between	the	two	groups.	To	do	so,	for	each	of	the	assays	we	generated	
simulated	 data	 based	 on	 the	 distributions	 observed	 in	 our	 study,	 separately	 analysing	 cases	
and	controls.	Using	a	guideline	formula	calculated	as	described	by	Peduzzi	[32],	the	predicted	
minimum	number	of	samples	per	group	was	140. All	tests	and	analyses	were	performed	using	
the	statistical	software	R	,	including	the	pROC	packages	[33]. 
	
Results	
Plasma	levels	of	FH	and	TCC	distinguish	epileptic	patients	from	controls	
Of	 eleven	 complement	 analytes	 measured,	 two	 (FH	 and	 TCC)	 were	 individually	 significantly	
different	 between	 the	 focal	 and	 generalised	 epilepsy	population	 in	 comparison	with	healthy	
controls	(Table	3).	Both	FH	and	TCC	plasma	levels	were	significantly	increased	in	cases	(for	FH,	
controls	 235.80	 µg/ml;	 focal	 epilepsy	 301.29	 µg/ml,	 generalised	 epilepsy	 294.03	 µg/ml,	 p<	
0.001;	 for	 TCC,	 controls	 15.99	 µg/ml;	 focal	 epilepsy	 20.66	 µg/ml,	 generalised	 epilepsy	 19.21	
µg/ml,	 p=	 0.002).	 TCC	 and	 FH	were	 strongly	 co-correlated	 (Spearman	 correlation	 coefficient	
0.48).	
	
Analysis	of	difference	in	complement	levels	between	epilepsy	types	
The	above	results	show	significant	differences	in	concentrations	of	two	complement	analytes	
between	 all	 epilepsy	 patients	 and	 healthy	 controls.	 We	 then	 tested	 whether	 differences	 in	
complement	levels	occur	between	epilepsies	with	different	aetiologies.	The	results	presented	
in	 Table	 4	 show	 that	 there	 was	 no	 statistical	 difference	 between	 the	 focal	 and	 generalised	
epilepsy	groups	in	regards	to	the	complement	analyte	concentrations.	
	
Logistic	regression	and	receiver	operating	characteristics	(ROC)	analysis	
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To	 find	 the	 set	 of	 analytes	 and	 demographics	 that	 best	 distinguished	 epilepsy	 patients	 and	
controls,	 different	 combinations	 were	 tested	 in	 multiple	 logistic	 regression	 models.	 The	
resulting	stepwise-selected	model	comprised	six	analytes:	C3,	C4,	Properdin,	FH,	C1Inh	and	Clu.	
Although	 TCC	 was	 highly	 significant	 in	 the	 univariate	 analysis,	 it	 is	 not	 included	 in	 this	
multivariate	model;	this	might	be	due	to	the	fact,	noted	above,	that	it	is	highly	correlated	with	
FH,	and	also	with	C3	and	C4.	In	the	model,	the	predictive	information	carried	by	TCC	is	already	
carried	by	FH	 (and	perhaps	C3	and	C4),	and	 thus	TCC	does	not	add	more	 information	 to	 the	
model.	Clusterin,	despite	not	being	significant	 in	the	univariate	tests	 (significant	at	p<0.1	but	
not	p<0.05),	was	included	in	the	model	because	it	improved	performance.		
To	 study	 the	 accuracy	 and	 performance	 of	 the	 selected	 model,	 we	 performed	 ROC	 curve	
analysis.	We	computed	and	compared	the	AUC	for	four	different	models:	the	stepwise	selected	
model	 (C3,	 C4,	 Properdin,	 FH,	 C1Inh	 and	 Clu);	 the	 full	 model	 with	 all	 the	 variables	 (eleven	
complement	 analytes	 and	 demographics);	 the	model	with	 only	 age	 and	 sex	 (demographics);	
and	 the	 model	 with	 only	 the	 eleven	 complement	 analytes.	 The	 different	 ROC	 curves	 are	
provided	 in	 Figure	 1A.	 All	 four	 ROC	 curves	 have	 been	 computed	 after	 leave-one-out	 cross-
validation.	 The	most	 accurate	model	was	 the	 stepwise	 selected	model	 (AUC=0.80),	whereas	
the	 full	model	 and	 the	model	 including	 the	 eleven	 analytes	 only	were	 slightly	 less	 accurate	
(AUC=0.78).	 Finally,	 the	 model	 with	 only	 the	 demographics	 provided	 poor	 performance	
(AUC=0.56).	As	 the	 full	model	and	assay	model	were	equally	accurate	and	varied	only	 in	 the	
absence	 or	 presence	 of	 the	 demographics	 information,	 we	 can	 conclude	 that	 there	 is	 no	
significant	age	or	sex	effect	for	epilepsy	in	the	samples	analysed.	
	
There	are	differences	in	complement	analyte	levels	in	patients	with	uncontrolled	seizures	
We	next	investigated	whether	complement	levels	differed	with	the	level	of	seizure	control.	We	
identified	 significant	 differences	 in	 complement	 levels	 between	 patients	 with	 controlled	
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seizures	 compared	 to	 those	 with	 uncontrolled	 seizures	 (Table	 5).	 Levels	 of	 iC3b	 (p=	 0.02),	
Properdin	 (p=	0.05)	and	Clu	 (p=	0.02)	were	significantly	decreased	and	 levels	of	C4	 (p=	0.02)	
were	significantly	increased	in	patients	with	uncontrolled	seizures.	There	was	a	trend,	although	
not	 statistically	 significant,	 to	 increased	 level	 of	 C1q	 (p=	 0.07)	 in	 cases	 with	 uncontrolled	
seizures.	A	stepwise	logistic	regression	model	was	computed	to	find	a	set	of	analytes	that	best	
distinguished	the	two	groups.	The	resulting	model	comprised	age	(patients	with	uncontrolled	
seizures	were	older)	alongside	iC3b,	C3,	C4,	Properdin	and	CRP.	Despite	its	significance	in	the	
univariate	 analysis,	 Clu	 is	 not	 included,	 likely	 because	 it	 highly	 correlated	with	 Properdin.	 A	
ROC	curve	analysis,	with	leave-one-out	cross-validation,	was	performed	as	above;	the	AUC	for	
the	model	was	 0.73,	wheras	 demographic	 variables	 (age	 and	 gender)	 alone	 gave	 an	AUC	of	
0.61	 (Figure	 1B).In	 those	 with	 uncontrolled	 seizures,	 there	 was	 no	 significant	 correlation	
between	 complement	 levels	 and	 type	 or	 frequency	 of	 seizures,	 although	 group	 sizes	 in	 this	
analysis	were	small.		
	
Associations	between	anti-epileptic	drug	therapy	and	complement	analytes	
Several	studies	describe	the	effects	of	antiepileptic	drugs	(AEDs)	on	the	immune	system	[34,35].	
We	investigated	the	correlation	between	1)	the	number	of	AEDs	taken,	and	2)	different	AEDs	
(for	those	groups	where	we	had	greater	than	15	patients	taking	any	particular	drug)	and	the	
plasma	 levels	of	 complement	 analytes.	We	 tested	 this	 in	patients	 taking	 the	 following	drugs	
(within	 parenthesis	 the	 number	 of	 patients	 taking	 the	 given	 drug):	 levetiracetam	 (67),	
lamotrigine	(55),	sodium	valproate	(36),	clobazam	(36),	zonisamide	(21),	carbamazepine	(18),	
eslicarbazepine	(17),	perampanel	(16),	topiramate	(15).	Spearman	correlation	analysis	showed	
no	 correlation	between	 the	 levels	of	 complement	biomarkers	and	 the	 total	number	of	AEDs	
taken.	An	association	between	levels	of	some	analytes	and	drug	therapy	was	seen	in	patients	
taking	 sodium	 valproate	 (elevated	 iC3b,	 p=	 0.0076),	 clobazam	 (elevated	 CRP,	 p=	 0.09),	 and	
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perampanel	 (elevated	 TCC,	 p=0.001	 and	 Properdin,	 p=0.001).	 No	 significant	 differences	 in	
complement	analyte	concentrations	were	observed	for	the	other	AEDs	tested.		
	
Discussion	
To	 our	 knowledge,	 this	 is	 the	 first	 study	 investigating	 plasma	 concentrations	 of	 a	 panel	 of	
complement	analytes	in	epilepsy.	We	chose	a	set	of	analytes	that	included	markers	of	classical,	
alternative	and	terminal	activation	pathways.	We	report	an	association	of	higher	FH	and	TCC	in	
adults	with	epilepsy	compared	to	controls	and	present	a	highly	predictive	model	 (AUC	0.8	 in	
ROC	analysis)	comprising	6	complement	analytes (C3,	C4,	Properdin,	FH,	C1Inh	and	Clu)	 that	
distinguish	between	epilepsy	cases	and	controls.	We	show	that	complement	biomarkers	also	
distinguish	patients	with	well-controlled	epilepsy	from	those	with	poorly	controlled	disease;	a	
model	comprising	five	analytes	(iC3b,	C3,	C4,	Properdin	and	CRP)	gave	an	AUC	of	0.73.	We	also	
tested	the	influence	of	specific	AEDs	on	complement	analytes.	
	
C3	 and	 C4	 are	 the	 two	 most	 abundant	 complement	 proteins,	 C4	 a	 key	 component	 of	 the	
classical	 activation	 pathway	 and	 C3	 occupying	 a	 cornerstone	 position	 where	 all	 activation	
pathways	converge;	both	are	important	sources	of	opsonic	activity.	All	of	the	other	analytes	in	
the	marker	set	distinguishing	cases	 from	controls	are	complement	 regulators,	C1inh	 the	sole	
plasma	 regulator	of	 classical	pathway	 initiation,	 FH	and	properdin	 controlling	 the	alternative	
pathway	 amplification	 loop,	 and	 Clu	 regulating	 the	 terminal	 pathway.	 FH	 regulates	
complement	both	in	the	fluid	phase	and	on	self	cells;	capture	of	FH	on	self	cells	is	important	in	
defence	against	damage,	while	pathogen	capture	of	FH	reduces	complement	activation	aiding	
pathogen	 survival.	 Dysregulation	 of	 the	 alternative	 pathway	 has	 been	 reported	 in	 other	
neurological	and	neuropsychiatric	disorders,	 including	schizophrenia	[36],	and	altered	plasma	
FH	 levels	are	a	marker	of	multiple	 sclerosis	 [37].	TCC	 levels	 reflect	activation	of	 the	 terminal	
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pathway	that	deposits	the	lytic	membrane	attack	complex	(MAC)	on	pathogens;	MAC	can	also	
damage	or	activate	self	cells.	A	direct	role	in	epilepsy	was	suggested	by	the	demonstration	that	
infusion	 of	 individual	 MAC	 proteins	 into	 the	 hippocampus	 of	 rats	 induced	 cytotoxicity	 and	
seizures	[28].	
	
Complement	has	recently	emerged	as	a	key	player	in	brain	development;	C1q	and	downstream	
classical	pathway	products	mark	synapses	for	elimination	during	post-natal	brain	remodelling,	
a	process	that	is	essential	for	brain	development,	maturation,	and	optimal	function	[37].	This	
physiological	 process	 has	 also	 been	 implicated	 in	 pathological	 synapse	 elimination	 in	 the	
context	 of	 schizophrenia	 and	 dementia	 [37-39].	 Increased	 levels	 of	 C1q	 and	 iC3b	 (classical	
complement	 pathway	 markers)	 were	 reported	 in	 human	 brain	 samples	 in	 focal	 cortical	
dysplasia	 [31],	 suggesting	 that	 aberrant	 complement	 activation	 occurs	 in	 patients	with	 drug	
resistant	 seizures.	Our	 current	 study	 suggests	 that	 dysregulation	 of	 the	 classical	 (C1inh,	 C4),	
alternative	 (FH,	 properdin,	 C3)	 and	 terminal	 (TCC)	 pathways	 also	 contribute	 to	 epilepsy	
pathogenesis.		
	
Our	data	suggest	that	dysregulation	of	the	classical	pathway	may	be	a	feature	of	poor	seizure	
control;	 there	was	a	significant	 increase	 in	plasma	C4	and	trending	 increased	C1q	 in	patients	
with	 uncontrolled	 seizures	 compared	 to	 those	 with	 controlled	 seizures.	 It	 is,	 however,	
unknown	whether	 the	 observed	 changes	 are	 a	 driver	 or	 consequence	 of	 seizures,	 the	 latter	
perhaps	 reflecting	 a	 response	 to	 brain	 or	 peripheral	 tissue	 injury.	 Indeed,	 it	 is	 possible	 that	
changes	 in	analyte	 levels	occurred	as	a	consequence	of	 recent	seizures.	We	had	an	accurate	
record	of	seizure	frequency	from	the	clinic	records	at	the	time	of	sampling;	however,	this	did	
not	always	include	the	precise	interval	between	the	most	recent	seizure	and	the	sample.	We	
were	therefore	unable	to	correlate	our	measures	with	seizure	recency;	however,	we	were	able	
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to	 test	against	 seizure	 frequency	 (or	 type)	and	did	not	 find	a	 significant	correlation	between	
these	and	analyte	levels.	Furthermore,	the	majority	of	our	cases	were	recruited	and	sampled	at	
routine	 outpatient	 visits,	 making	 it	 unlikely	 that	 our	 findings	 were	 a	 direct	 consequence	 of	
recent	seizures.	
	
A	limitation	of	our	study	is	the	heterogeneity	of	the	epilepsy	sample	in	regards	to	the	disease	
aetiology	and	drug	treatment.	We	decided	on	an	“all	comers”	data	driven	approach	as	an	initial	
analysis	 in	 this	 area.	 We	 examined	 the	 effects	 of	 disease	 severity	 (seizure	 frequency)	 and	
specific	 drug	 therapies.	 Some	AEDs,	 including	 valproate	 and	 carbamazepine,	 are	 reported	 to	
have	direct	effects	on	the	immune	system	[35].	In	our	study,	sodium	valproate,	clobazam,	and	
perampanel	 were	 associated	 with	 changes	 in	 levels	 of	 individual	 complement	 analytes;	
however,	groups	of	patients	 taking	 individual	drugs	were	too	small	 (sodium	valproate	n=	36,	
clobazam	n=	36,	perampenel	n=	16)	for	statistical	analysis	to	be	conclusive.	A	further	limitation	
is	that	this	 is	a	study	of	circulating	plasma	biomarkers	and	we	are	using	these	to	probe	what	
may	be	happening	within	the	CNS.	However,	it	has	long	been	established	that	the	blood-brain	
barrier	in	epilepsy	is	dysfunctional	and	leaky	[40,41],	thus	the	use	of	plasma	biomarkers,	which	
are	much	more	easily	accessible	and	measurable,	is	well-founded.	Moreover,	the	dysregulation	
of	 complement	 described	 in	 our	 study	 closely	 mirrors	 changes	 identified	 in	 epilepsy	 brain	
tissue	in	humans	and	in	animal	models	[26,28].		
	
In	order	to	confirm	our	findings	and	to	tease	out	the	effect	of	AEDs	on	complement	biomarker	
levels,	a	replication	set,	focussing	on	the	informative	analytes,	is	needed.	We	need	in	future	to	
access	 samples	 from	early	 diagnosis	 patients,	 ideally	 recruiting	 patients	 promptly	 after	 their	
first	 seizure.	A	prospective	 study	with	 frequent	measurements	of	plasma	complement	 levels	
would	be	beneficial	for	identification	of	dynamic	changes	in	complement	and	would	provide	a	
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more	 reliable	 analysis	 of	 the	 impact	 of	 complement	 dysregulation	 on	 seizure	 frequency	 and	
type.	
	
Conclusion	
Significant	differences	were	found	in	a	number	of	complement	analytes	between	patients	with	
epilepsy	 and	 controls,	 controlled	 and	 uncontrolled	 epilepsy,	 and	 certain	 AEDs.	 Multivariate	
analyses	 identified	 highly	 predictive	models	 for	 distinguishing	 cases	 from	 controls	 and	well-
controlled	 from	 uncontrolled	 cases.	 These	 data	 adds	 further	 evidence	 to	 the	 role	 of	
complement	dysregulation	in	the	pathogenesis	of	epilepsy	and	may	allow	the	development	of	
better	prognostic	markers	and	therapeutics	in	the	future.		
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Table	Legends	
Table	 1.	Distribution	 of	 diagnosis	 and	 aetiology	 of	 epilepsy	 for	 the	 study	 patients.	 For	 three	
patients	more	than	one	aetiology	was	indicated.	
	
Table	 2.	 The	 table	 lists	 the	 antibody	 pairs	 used	 in	 the	 multiplex	 sets,	 the	 sources	 of	 the	
antibodies	 and	 the	 standards,	 dilutions	 and	 assay	 working	 range.	MM	 -	 mouse	monoclonal	
antibody,	RP	-	rabbit	polyclonal	antibody,	HRP	-	horseradish	peroxidase	(antibodies	labelled	in-
house),	TCC	–	terminal	complement	complex;	C1Inh	–	C1	inhibitor;	FB	–	Factor	B;	FH	–	Factor	H;	
Clu	-	clusterin;	CRP	–	C-reactive	protein.	A	kind	gift	from	SRdC	–	Prof	S.	Rodriguez	de	Cordoba,	
Madrid.	 ECACC:	 European	 Collection	 of	 Authenticated	 Cell	 Cultures,	 Hycult:	
http://www.hycultbiotech.com/;	CompTech:	http://www.complementtech.com/.	
	
Table	3.	Complement	analyte	differences	between	epilepsy	patients	and	controls.	Significance	
of	differences	was	tested	using	the	Kruskal-Wallis	test.	Variables	significant	at	p	=	0.05	are	in	
bold	and	underlined.	TCC	–	terminal	complement	complex;	C1Inh	–	C1	inhibitor;	FB	–	Factor	B;	
FH	 –	 Factor	 H;	 Clu	 -	 clusterin;	 CRP	 –	 C-reactive	 protein.	 Post-hoc	 pairwise	 comparisons,	
performed	using	the	Dunn	test	with	Bonferroni	correction,	showed	that	TCC	was	significantly	
reduced	 in	controls	compared	 to	both	 focal	 (p	=	0.0011)	and	generalised	cases	 (p	=	0.0077),	
and	FH	was	also	significantly	different	in	both	comparisons		(p	<	0.001	for	both).	
	
Table	 4.	 Complement	 analyte	 differences	 between	 focal	 epilepsy	 patients	 and	 generalised	
epilepsy	patients.	Significance	of	differences	was	tested	using	the	Mann-Whitney	U-test.	TCC	–	
terminal	 complement	 complex;	 C1Inh	 –	 C1	 inhibitor;	 FB	 –	 Factor	 B;	 FH	 –	 Factor	 H;	 Clu	 -	
clusterin;	CRP	–	C-reactive	protein.		
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Table	 5.	 Complement	 analyte	 differences	 between	 controlled	 and	 uncontrolled	 seizure	
epilepsy.	 Significance	 of	 differences	 was	 tested	 using	 the	 Mann-Whitney	 U-test.	 Variables	
significant	at	p=	0.05	are	in	bold	and	underlined.	TCC	–	terminal	complement	complex;	C1Inh	–	
C1	inhibitor;	FB	–	Factor	B;	FH	–	Factor	H;	Clu	-	clusterin;	CRP	–	C-reactive	protein.		
	
	
Figure	legend	
	
Figure	1.	A.	Receiver	operated	characteristic	(ROC)	curves	to	predict	the	probability	of	epilepsy	
(combined	 focal	 and	 generalised)	 compared	 to	 control	 subjects.	 Four	 different	 models	 are	
presented:	the	stepwise	selected	model	(model	chosen);	the	full	model	with	all	the	variables;	
the	 model	 with	 only	 age	 and	 gender	 (demographics);	 and	 the	 model	 with	 only	 the	 eleven	
complement	 assays.	 The	 most	 accurate	 model	 is	 the	 stepwise	 selected	 model	 (AUC=0.80),	
followed	 by	 the	 full	model	 and	 the	model	 including	 the	 eleven	 assays	 only	 (AUC=0.78).	 The	
model	with	only	the	demographics	provides	poor	performance	(AUC=0.56).		
B.	 ROC	 curves	 for	 controlled	 versus	 uncontrolled	 cases:	 Two	 models	 are	 presented,	 the	
selected	 model	 (age	 alongside	 iC3b,	 C3,	 C4,	 Properdin,	 CRP)	 and	 the	 model	 with	 only	 the	
demographics	variables.	The	selected	model	is	significantly	more	accurate	(AUC=0.73)	than	the	
model	with	demographics	alone	(AUC=0.61).	
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Table	1.	
Diagnosis	(syndrome)	
Number	 of	 patients,	 n	
(%)	
Temporal	lobe	epilepsy	 61	(38%)	
Juvenile	myoclonic	epilepsy	 29	(18%)	
Frontal	lobe	epilepsy	 21	(13%)	
Focal	epilepsy	–	not	localised	 23	(14%)	
Idiopathic	generalised	epilepsy		 8	(5%)	
Epilepsy	with	generalised	tonic	clonic	seizures	alone	 5	(3%)	
Juvenile	absence	epilepsy	 4	(2%)	
Occipital	lobe	epilepsy	 1(0.64%)	
Single	epileptic	seizure	 1	(0.64%)	
Unclassified	epileptic	seizures	 4	(2%)	
	
Aetiology	
Number	 of	 patients,	 n	
(%)	
Hippocampal	sclerosis	 30	(19%)	
Focal	cortical	dysplasia	 6	(3%)	
Cerebral	arteriovenous	malformation	 3	(1.9%)	
Closed	injury	of	head	 3	(1.9%)	
Dysembryoplastic	neuroepithelial	tumour	 3	(1.9%)	
Other	structural	abnormalities	 18	(11%)	
Idiopathic	(presumed	genetic)	or	Unknown	 97	(61.78%)	
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Table	 2.
Assay	 Capture	Antibody	 Detection	Antibody	 Standard		 Working	range	(ng/mL)	 Sample	dilution	
C1q	 MM	anti-C1q	mAb	(WL02,	Hycult)	 MM	anti-C1q	(DJ01,	Hycult)-HRP	 C1q	(in-house	purified)	 32-1000	 1:1000	
C3	 RP	anti	Human	C3	(in-house)	 RP	anti-C3	(in-house)-HRP	 C3	(CompTech)	 32-1000	 1:16000	
C4	 RP	anti-C4	(in-house)	 RP	anti-C4	(in-house)-HRP	 C4	(CompTech)	 8-500	 1:4000	
Factor	B	 MM	anti-FB	(JC1;	in	house)	 MM	anti-FB	(MBI-5;	in-house)-HRP	 FB	(in-house	purified)	 64-1000	 1:500	
Factor	H	 MM	anti-FH	(OX24;	ECACC)	 MM	anti-FH	(35H9;	in-house)-HRP	 FH	(in-house	purified)	 16-1000	 1:3000	
C1inh	 MM	anti-C1inh	(in-house)	 RP	anti-C1inh	(in-house)-HRP	
C1	inhibitor	(Cinryze	
drug)	
4-100	 1:16000	
Properdin	
MM	anti-Properdin	(1.1.1;	Gift	of	
SRdC)	
MM	anti-Properdin	(12-14-2;	gift	
of	SRdC)-HRP	
Properdin	(CompTech)	 7-100	 1:400	
TCC	 MM	anti-TCC	(aE11,	Hycult)	 MM	anti	C8	(E2,	in-house)-HRP	 TCC	(in-house	purified)	 60-1000	 1:50	
iC3b	 MM	anti-iC3b	(Clone	9;	in	house)	 MM	anti-iC3b	(bH6;	in	house)-HRP	 iC3b	(CompTech)	 32-1000	 1:50	
Clusterin	
MM	anti-clusterin	(R&D	Systems;	
DuoSet)	
Biotinylated	MM	anti-clusterin-
Biotin	(R&D;	DuoSet)	
Clusterin	(R&D	Systems;	
DuoSet)	
3-50	 1:16000	
CRP	 MM	anti-CRP	(R&D	Systems;	DuoSet)	
MM	anti-CRP-Biotin	/	Avidin-HRP	
(R&D	Systems;	DuoSet)			
CRP	(R&D	Systems;	
DuoSet)	
0.8-50	 1:600	
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Table	3.	
Assay	 Control	 Focal	 Generalised	 p-value	
	 Mean	 StDev	 Mean	 StDev	 Mean	 StDev	 	
TCC	 15.99	 6.54	 20.66	 10.2	 19.21	 6.55	 0.002	
iC3b	 56.06	 51.22	 53.43	 32.06	 54.52	 31.49	 0.22	
C1q	 114.46	 54.54	 114.16	 61.6	 108.94	 45.9	 0.91	
C3	 1651.78	 371.16	 1716.54	 317.54	 1662.12	 308.74	 0.36	
C4	 401.16	 94.81	 396.44	 89.34	 386.6	 95.9	 0.42	
Properdin	 10.569	 2.233	 10.33	 2.801	 10.178	 2.545	 0.59	
FB	 117.67	 35.02	 126.72	 52.3	 120.26	 48.01	 0.63	
FH	 235.8	 62.11	 301.29	 67.1	 294.03	 61.42	 <	0.001	
C1inh	 160.62	 34.51	 172.98	 34.93	 164.56	 30.04	 0.12	
CRP	 1.83	 6.028	 1.61	 1.92	 1.17	 1.48	 0.3	
Clu	 475.37	 221.05	 434.293	 178.08	 446.09	 166.97	 0.76	
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Table	4.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
Assay	 Focal	 Generalised	 p-value	
	 Mean	 StDev	 Mean	 StDev	 	
TCC	 20.66	 10.2	 19.21	 6.55	 0.9	
iC3b	 53.43	 32.06	 54.52	 31.49	 0.79	
C1q	 114.16	 61.6	 108.94	 45.9	 0.68	
C3	 1716.54	 317.54	 1662.12	 308.74	 0.28	
C4	 396.44	 89.34	 386.6	 95.9	 0.28	
Properdin	 10.33	 2.801	 10.178	 2.545	 0.59	
FB	 126.72	 52.3	 120.26	 48.01	 0.44	
FH	 301.29	 67.1	 294.03	 61.42	 0.72	
C1inh	 172.98	 34.93	 164.56	 30.04	 0.18	
CRP	 1.61	 1.92	 1.17	 1.48	 0.21	
Clu	 434.293	 178.08	 446.09	 166.97	 0.66	
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Table	5	
Assay	 Controlled	 Uncontrolled	 p-value	
	 Mean	 StDev	 Mean	 StDev	 	
TCC	 20.47	 10.33	 20.03	 8.41	 0.74	
iC3b	 61.06	 37.16	 48.3	 26	 0.02	
C1q	 109.48	 71.66	 114.9	 43.72	 0.07	
C3	 1747.22	 333.3	 1664.84	 297.46	 0.19	
C4	 372.86	 84.97	 408.86	 93.06	 0.02	
Properdin	 10.695	 2.695	 9.977	 2.711	 0.05	
FB	 123.34	 44.35	 125.83	 55.63	 0.81	
FH	 300.23	 69.33	 298.24	 62.54	 0.83	
C1inh	 170.26	 31.63	 170.56	 35.27	 0.85	
CRP	 1.28	 1.42	 1.62	 2.02	 0.49	
Clu	 472.37	 184.45	 412.07	 162.69	 0.02	
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Figure 1. 
A B 	
 
	
